Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 473

1.

Genetic profile and functional proteomics of anal squamous cell carcinoma: proposal for a molecular classification.

Trilla-Fuertes L, Ghanem I, Gámez-Pozo A, Maurel J, G-Pastrian L, Mendiola M, Peña C, Lopez-Vacas R, Prado-Vazquez G, Lopez-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, Garcia-Alfonso P, Capdevila J, Conill C, Garcia-Carbonero R, Ramos-Ruiz R, Fortes C, Llorens C, Nanni P, Fresno Vara JA, Feliu J.

Mol Cell Proteomics. 2020 Feb 27. pii: mcp.RA120.001954. doi: 10.1074/mcp.RA120.001954. [Epub ahead of print]

2.

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

Aparicio J, Virgili A, Capdevila J, Muñoz Boza F, Álvarez R, Bosch C, Cámara J, Fernandez-Martos C, Fernandez-Plana J, Gallego J, Gallego R, Hernández-Yagüe X, Macías Declara I, Rodríguez-Salas N, Vera R, Taberner M, Maurel J.

Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4. No abstract available.

PMID:
32085197
3.

Clinical and Translational Challenges in Thyroid Cancers

Hernando J, Ros J, Arroyo A, Capdevila J.

Curr Med Chem. 2020 Feb 14. doi: 10.2174/0929867327666200214125712. [Epub ahead of print]

PMID:
32056516
4.

The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).

Grande E, Teulé A, Alonso-Gordoa T, Jiménez-Fonseca P, Benavent M, Capdevila J, Custodio A, Vera R, Munarriz J, La Casta A, Díez JJ, Gajate P, Molina-Cerrillo J, Matos I, Cristóbal EM, Ruffinelli JC, Palacios J, García-Carbonero R.

Oncologist. 2020 Feb 11. doi: 10.1634/theoncologist.2020-0033. [Epub ahead of print]

5.

SEOM clinical guideline thyroid cancer (2019).

Gallardo E, Medina J, Sánchez JC, Viúdez A, Grande E, Porras I, Ramón Y Cajal T, Trigo J, Iglesias L, Capdevila J.

Clin Transl Oncol. 2020 Feb;22(2):223-235. doi: 10.1007/s12094-019-02284-8. Epub 2020 Jan 31.

PMID:
32006340
6.

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.

Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME; CLARINET Study Group.

Anticancer Drugs. 2020 Mar;31(3):216-222. doi: 10.1097/CAD.0000000000000909.

7.

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).

Feliu J, Garcia-Carbonero R, Capdevila J, Guasch I, Alonso-Orduna V, Lopez C, Garcia-Alfonso P, Castanon C, Sevilla I, Cerezo L, Conill C, Quintana-Angel B, Sanchez ME, Ghanem I, Martin-Richard M, Lopez-Gomez M, Leon A, Caro M, Fernandez T, Maurel J.

Cancer Med. 2020 Feb;9(3):1008-1016. doi: 10.1002/cam4.2722. Epub 2019 Dec 18.

8.

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.

Capdevila J, Arqués O, Hernández Mora JR, Matito J, Caratù G, Mancuso FM, Landolfi S, Barriuso J, Jimenez-Fonseca P, Lopez Lopez C, Garcia-Carbonero R, Hernando J, Matos I, Paolo N, Hernández-Losa J, Esteller M, Martínez-Cardús A, Tabernero J, Vivancos A, Palmer HG.

Clin Cancer Res. 2020 Feb 15;26(4):902-909. doi: 10.1158/1078-0432.CCR-19-1266. Epub 2019 Oct 31.

9.

Positive-pressure needleless connectors did not increase rates of catheter hub colonization respecting the use of neutral-pressure needleless connectors in a prospective randomized trial.

Delgado M, Capdevila JA, Sauca G, Méndez J, Rodriguez A, Yébenes JC; Sepsis, Inflammation, Safety Research Group (Gr-Sis, Agaur 2014-Sgr926).

Enferm Infecc Microbiol Clin. 2020 Mar;38(3):119-122. doi: 10.1016/j.eimc.2019.07.012. Epub 2019 Oct 24. English, Spanish.

PMID:
31668861
10.

Inadequate empirical antimicrobial treatment in older people with bacteremic urinary tract infection who reside in nursing homes: A multicenter prospective observational study.

Gómez Belda AB, De la Fuente J, Diez LF, Capdevila JA, Inglada L, Arca A, Romero JM, Serra-Centelles C, Domínguez-Gil M, Artero A.

Geriatr Gerontol Int. 2019 Nov;19(11):1112-1117. doi: 10.1111/ggi.13776. Epub 2019 Oct 1.

PMID:
31571357
11.

Interhospital Sepsis Code in Catalonia (Spain): Territorial model for initial care of patients with sepsis.

Yébenes JC, Lorencio C, Esteban E, Espinosa L, Badia JM, Capdevila JA, Cisteró B, Moreno S, Calbo E, Jiménez-Fábrega X, Clèries M, Faixedas MT, Ferrer R, Vela E, Medina C, Rodríguez A, Netto C, Armero E, Solsona M, Lopez R, Granes A, Perez-Claveria V, Artigas A, Estany J; Comisión Asesora para la Atención al Paciente con Sepsis y Grup de Treball de Sèpsia i Xoc Sèptic (GTSiXS) SOCMIC-SOCMUE.

Med Intensiva. 2020 Jan - Feb;44(1):36-45. doi: 10.1016/j.medin.2019.05.008. Epub 2019 Sep 19. English, Spanish.

PMID:
31542182
12.

Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial.

Capdevila J, Matos I, Mancuso FM, Iglesias C, Nuciforo P, Zafon C, Palmer HG, Ogbah Z, Muiños L, Hernando J, Villacampa G, Peña CE, Tabernero J, Brose MS, Schlumberger M, Vivancos A.

Mol Cancer Ther. 2020 Jan;19(1):312-317. doi: 10.1158/1535-7163.MCT-19-0211. Epub 2019 Sep 20.

PMID:
31540966
13.

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).

Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, Alonso Gordoa T, Nuñez-Valdovino B, Sanchez Canovas M, Matos I, Alonso V, Lopez C, Viudez A, Izquierdo M, Calvo-Temprano D, Grande E, Capdevila J, Jimenez-Fonseca P.

Br J Cancer. 2019 Oct;121(7):537-544. doi: 10.1038/s41416-019-0558-7. Epub 2019 Sep 3.

14.

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.

Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, Martin-Richard M, Alonso-Orduña V, Vera R, Gallego J, Capdevila J, Salud A, Nogué M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2294. [Epub ahead of print]

PMID:
31465088
15.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.

Ann Oncol. 2019 Nov 1;30(11):1846. doi: 10.1093/annonc/mdz219. No abstract available.

PMID:
31407000
16.

Early evolutionary divergence between papillary and anaplastic thyroid cancers.

Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J.

Ann Oncol. 2019 Nov 1;30(11):1843. doi: 10.1093/annonc/mdz216. No abstract available.

PMID:
31406995
17.

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.

Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R.

J Clin Oncol. 2019 Oct 1;37(28):2571-2580. doi: 10.1200/JCO.19.00980. Epub 2019 Aug 7.

18.

Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.

Capdevila J, Hernando J, Perez-Hoyos S, Roman-Gonzalez A, Grande E.

Oncologist. 2019 Dec;24(12):e1315-e1320. doi: 10.1634/theoncologist.2018-0675. Epub 2019 Jul 22.

19.

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.

Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A.

Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.

20.

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.

Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I.

Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5.

PMID:
31199501
21.

Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis.

Vuong HG, Ho ATN, Tran TTK, Capdevila J, Benekli M, Nakazawa T, Katoh R, Kondo T.

Head Neck. 2019 Aug;41(8):2823-2829. doi: 10.1002/hed.25832. Epub 2019 Jun 4. Review.

PMID:
31162772
22.

Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

Garcia-Carbonero R, Marquez-Rodas I, de la Cruz-Merino L, Martinez-Trufero J, Cabrera MA, Piulats JM, Capdevila J, Grande E, Martin-Algarra S, Berrocal A.

Oncologist. 2019 Oct;24(10):1375-1383. doi: 10.1634/theoncologist.2018-0718. Epub 2019 Apr 8. Review.

23.

Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review.

Grande E, Díaz Á, López C, Munarriz J, Reina JJ, Vera R, Bernárdez B, Aller J, Capdevila J, Garcia-Carbonero R, Jimenez Fonseca P, Trapero-Bertran M.

Ther Adv Endocrinol Metab. 2019 Feb 18;10:2042018819828217. doi: 10.1177/2042018819828217. eCollection 2019. Review.

24.

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.

Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, Singh S, Fazio N, He W, Riester M, Patel P, Voi M, Morrissey M, Pavel M, Kulke MH.

Endocr Relat Cancer. 2019 Apr 1;26(4):391-403. doi: 10.1530/ERC-18-0332. Epub 2019 Jan 1.

PMID:
30667365
25.

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.

Jiménez-Fonseca P, Martín MN, Carmona-Bayonas A, Calvo A, Fernández-Mateos J, Redrado M, Capdevila J, Lago NM, Lacasta A, Muñarriz J, Segura Á, Fuster J, Barón F, Llanos M, Serrano R, Castillo A, Cruz Hernández JJ, Grande E.

Oncotarget. 2018 Dec 11;9(97):36894-36905. doi: 10.18632/oncotarget.26380. eCollection 2018 Dec 11.

26.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).

González-Flores E, Serrano R, Sevilla I, Viúdez A, Barriuso J, Benavent M, Capdevila J, Jimenez-Fonseca P, López C, Garcia-Carbonero R.

Clin Transl Oncol. 2019 Jan;21(1):55-63. doi: 10.1007/s12094-018-1980-7. Epub 2018 Dec 7.

27.

Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group.

de Herder WW, Capdevila J.

Neuroendocrinology. 2019;108(1):5-6. doi: 10.1159/000495036. Epub 2018 Dec 5. No abstract available.

28.

Differences in Hypotensive vs. Non-Hypotensive Sepsis Management in the Emergency Department: Door-to-Antibiotic Time Impact on Sepsis Survival.

Ballester L, Martínez R, Méndez J, Miró G, Solsona M, Palomera E, Capdevila JA, Rodriguez A, Yébenes JC.

Med Sci (Basel). 2018 Oct 10;6(4). pii: E91. doi: 10.3390/medsci6040091.

29.

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours.

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, García-Carbonero R, Grande E, Jimenez-Fonseca P, Marazuela M, Rodríguez-Antona C, Aller J.

Cancer Treat Rev. 2018 Nov;70:209-222. doi: 10.1016/j.ctrv.2018.09.008. Epub 2018 Sep 26. Review.

PMID:
30292979
30.

Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms.

Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):26-36. doi: 10.1159/000494258. Epub 2018 Oct 3. Review.

31.

The arachidonic acid monooxygenase: from biochemical curiosity to physiological/pathophysiological significance.

Capdevila JH, Falck JR.

J Lipid Res. 2018 Nov;59(11):2047-2062. doi: 10.1194/jlr.R087882. Epub 2018 Aug 28.

32.

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.

Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):18-25. doi: 10.1159/000493319. Epub 2018 Aug 28. Review.

33.

Concurrent palliative external radiotherapy with sorafenib or doxorubicin for bulky differentiated thyroid carcinoma: A case report.

Cortés-Mateus KS, Holub K, Racca F, Grau JJ, Capdevila J.

Oncol Lett. 2018 Sep;16(3):4085-4089. doi: 10.3892/ol.2018.9069. Epub 2018 Jul 4.

34.

High-fat diet-induced obesity and insulin resistance in CYP4a14-/- mice is mediated by 20-HETE.

Gilani A, Pandey V, Garcia V, Agostinucci K, Singh SP, Schragenheim J, Bellner L, Falck JR, Paudyal MP, Capdevila JH, Abraham NG, Laniado Schwartzman M.

Am J Physiol Regul Integr Comp Physiol. 2018 Nov 1;315(5):R934-R944. doi: 10.1152/ajpregu.00125.2018. Epub 2018 Aug 8.

35.

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J, Kreissl M, Aller J, Grande E.

Cancer Treat Rev. 2018 Sep;69:164-176. doi: 10.1016/j.ctrv.2018.06.019. Epub 2018 Jul 2. Review.

PMID:
30032061
36.

The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.

Sausville LN, Gangadhariah MH, Chiusa M, Mei S, Wei S, Zent R, Luther JM, Shuey MM, Capdevila JH, Falck JR, Guengerich FP, Williams SM, Pozzi A.

Cancer Res. 2018 Sep 1;78(17):4865-4877. doi: 10.1158/0008-5472.CAN-17-3977. Epub 2018 Jul 16.

37.

The right compound for the right target: tackling RET.

Seoane J, Capdevila J.

Ann Oncol. 2018 Aug 1;29(8):1623-1625. doi: 10.1093/annonc/mdy188. No abstract available.

38.

Detection of pancreatic neuroendocrine tumors: 23 years of experience.

Varas-Lorenzo MJ, Cugat E, Capdevila J, Sánchez-Vizcaíno Mengual E.

Rev Gastroenterol Mex. 2019 Jan - Mar;84(1):18-25. doi: 10.1016/j.rgmx.2018.02.015. Epub 2018 May 30. English, Spanish.

39.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.

Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators.

Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.

40.

Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.

Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, Jiménez-Fonseca P, Sevilla MI, Capdevila J.

Clin Transl Oncol. 2018 Dec;20(12):1522-1528. doi: 10.1007/s12094-018-1881-9. Epub 2018 May 15.

41.

Early evolutionary divergence between papillary and anaplastic thyroid cancers.

Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J.

Ann Oncol. 2018 Jun 1;29(6):1454-1460. doi: 10.1093/annonc/mdy123. Erratum in: Ann Oncol. 2019 Nov;30(11):1843.

42.

Impact of a training program on adherence to recommendations for care of venous lines in internal medicine departments in Spain.

Guembe M, Pérez-Granda MJ, Capdevila JA, Barberán J, Pinilla B, Bouza E; in behalf of the NUVE Study Group.

Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1163-1168. doi: 10.1007/s10096-018-3236-4. Epub 2018 Mar 22.

PMID:
29569044
43.

Executive summary: Diagnosis and Treatment of Catheter-Related Bloodstream Infection: Clinical Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) and the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC).

Chaves F, Garnacho-Montero J, Del Pozo JL, Bouza E, Capdevila JA, de Cueto M, Domínguez MÁ, Esteban J, Fernández-Hidalgo N, Fernández Sampedro M, Fortún J, Guembe M, Lorente L, Paño JR, Ramírez P, Salavert M, Sánchez M, Vallés J.

Enferm Infecc Microbiol Clin. 2018 Feb;36(2):112-119. doi: 10.1016/j.eimc.2017.10.019. English, Spanish.

PMID:
29412895
44.

Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC).

Chaves F, Garnacho-Montero J, Del Pozo JL, Bouza E, Capdevila JA, de Cueto M, Domínguez MÁ, Esteban J, Fernández-Hidalgo N, Fernández Sampedro M, Fortún J, Guembe M, Lorente L, Paño JR, Ramírez P, Salavert M, Sánchez M, Vallés J.

Med Intensiva. 2018 Jan - Feb;42(1):5-36. doi: 10.1016/j.medin.2017.09.012. English, Spanish.

45.

The clinical impact of bacteremia on outcomes in elderly patients with pyelonephritis or urinary sepsis: A prospective multicenter study.

Artero A, Inglada L, Gómez-Belda A, Capdevila JA, Diez LF, Arca A, Romero JM, Domínguez-Gil M, Serra-Centelles C, de la Fuente J.

PLoS One. 2018 Jan 24;13(1):e0191066. doi: 10.1371/journal.pone.0191066. eCollection 2018.

46.

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N.

Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.

47.

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R.

Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12.

48.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.

Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC.

Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.

49.

The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.

Amair-Pinedo F, Matos I, Saurí T, Hernando J, Capdevila J.

Target Oncol. 2017 Dec;12(6):757-774. doi: 10.1007/s11523-017-0532-3. Review.

PMID:
29143176
50.

Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.

Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkuhle JD, Gallagher RI, Petricoin EF Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA.

Cell Chem Biol. 2017 Oct 19;24(10):1314. doi: 10.1016/j.chembiol.2017.09.012. No abstract available.

Supplemental Content

Loading ...
Support Center